How to Get Compound Semaglutide: The Step-by-Step Process, Legal Requirements, and What Changed in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide requires a valid prescription from a licensed provider, state-specific pharmacy credentials, and active FDA shortage status (currently in effect through 2026)
• The legal pathway exists under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding when commercial supply cannot meet demand
• Total cost ranges from $250 to $450 per month including consultation, prescription, and medication, compared to $900+ for brand-name Wegovy or Ozempic
• Telehealth platforms reduced average time-to-first-dose from 14 days (2023) to 3-5 days (2026) by streamlining provider matching and pharmacy fulfillment

Direct answer (40-60 words)

Getting compounded semaglutide requires three steps: obtaining a prescription from a licensed provider (in-person or telehealth), verifying the pharmacy is licensed for sterile compounding under state and federal law, and confirming semaglutide remains on the FDA shortage list. The entire process takes 3 to 7 days through telehealth platforms, 7 to 14 days through traditional clinics.

Table of contents

1. The legal framework: why compounded semaglutide exists
2. Step 1: Getting a valid prescription
3. Step 2: Finding a legitimate compounding pharmacy
4. Step 3: Verifying FDA shortage status
5. The telehealth pathway vs traditional clinic pathway
6. Cost breakdown: what you actually pay
7. What most articles get wrong about compound semaglutide access
8. The state-by-state variation problem
9. When you cannot get compounded semaglutide (contraindications and restrictions)
10. The FormBlends 4-Gate Access Model
11. Insurance coverage: why it doesn't apply and what that means
12. FAQ
13. Sources

The legal framework: why compounded semaglutide exists

Compounded semaglutide is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits licensed pharmacies to compound medications when commercial supply cannot meet patient demand. The FDA added semaglutide to the drug shortage list in March 2023 and has renewed that designation every quarter since.

The shortage designation is not theoretical. Novo Nordisk's manufacturing capacity for Ozempic and Wegovy has been unable to keep pace with demand growth, which increased 450% between 2021 and 2024 (IQVIA prescription data, 2024). The company publicly acknowledged supply constraints in earnings calls throughout 2023 and 2024.

Under shortage conditions, Section 503A allows state-licensed compounding pharmacies to prepare semaglutide from bulk active pharmaceutical ingredient (API) sourced from FDA-registered suppliers. The compounded product is not FDA-approved and has not undergone the same review process as brand-name drugs. It is prepared in response to individual prescriptions, not manufactured in bulk.

The legal pathway closes when the FDA removes semaglutide from the shortage list. At that point, pharmacies must cease compounding under 503A. The FDA reviews shortage status quarterly. As of April 2026, semaglutide remains listed.

Three requirements must align for legal access:

1. Active FDA shortage designation. Verified at accessdata.fda.gov/scripts/drugshortages.
2. Valid prescription from a licensed provider. Telemedicine or in-person, but the provider must be licensed in your state.
3. Pharmacy licensed for sterile compounding. Must hold state Board of Pharmacy license and comply with USP 797 sterile compounding standards.

If any of the three conditions fails, the transaction is not legal under federal law.

Step 1: Getting a valid prescription

Semaglutide is a prescription medication. You cannot obtain it legally without a prescription from a licensed healthcare provider. The provider must be licensed in the state where you reside at the time of the consultation.

Eligible prescribers:

• Medical doctors (MD, DO)
• Nurse practitioners (NP)
• Physician assistants (PA)
• In some states, naturopathic doctors (ND) with prescribing authority

Clinical criteria for prescription:

The FDA-approved indications for semaglutide are type 2 diabetes (Ozempic) and chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea (Wegovy). Compounded semaglutide is prescribed off-label under the same clinical framework.

Most providers follow these criteria:

• BMI ≥30, or BMI ≥27 with weight-related comorbidity
• No history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• No personal or family history of pancreatitis
• Not pregnant or planning pregnancy within 2 months
• No severe gastroparesis or diabetic retinopathy complications

The consultation includes medical history review, current medications, contraindication screening, and discussion of risks and benefits. Most telehealth platforms complete this in a 10 to 15 minute asynchronous intake (you submit forms, provider reviews and responds) or a 15 to 20 minute video visit.

Prescription validity:

Semaglutide prescriptions are typically written for 90 days with refills. Some states limit controlled or high-risk medication prescriptions to 30 days, but semaglutide is not a controlled substance. The prescription must include:

• Patient name and date of birth
• Medication name (semaglutide), strength, and dosing instructions
• Quantity and refills
• Provider signature and DEA number (if applicable)
• Date of issue

Telehealth prescriptions are valid if the provider is licensed in your state and the consultation meets state telemedicine standards. All 50 states permit telemedicine prescribing for non-controlled medications as of 2026, though some require an initial in-person visit for new patients (Texas, Arkansas).

Step 2: Finding a legitimate compounding pharmacy

Not all pharmacies can compound semaglutide. The pharmacy must hold a state Board of Pharmacy license, comply with USP <797> sterile compounding standards, and source semaglutide API from an FDA-registered supplier.

What to verify before using a compounding pharmacy:

1. State pharmacy license. Search your state Board of Pharmacy website for the pharmacy's license number. Confirm it is active and in good standing. Out-of-state pharmacies can ship to you if they hold a license in your state or a reciprocal agreement exists.

1. USP <797> compliance. United States Pharmacopeia Chapter 797 sets standards for sterile compounding. Ask the pharmacy directly: "Are you USP 797 compliant?" Legitimate pharmacies will answer yes and provide documentation if requested.

1. API source verification. The semaglutide base powder must come from an FDA-registered supplier. The two primary suppliers in the U.S. market are Biocon Biologics and Novo Nordisk's bulk API division. Ask: "Where do you source your semaglutide API?" The pharmacy should disclose the supplier.

1. Accreditation (optional but preferred). Accreditation from the Pharmacy Compounding Accreditation Board (PCAB) or Accreditation Commission for Health Care (ACHC) is voluntary but indicates higher standards. About 30% of U.S. compounding pharmacies hold PCAB accreditation.

1. Inspection history. State Boards of Pharmacy conduct routine inspections. Ask if the pharmacy has had any citations, warnings, or suspensions in the past 3 years. Clean inspection history is a green flag.

Red flags:

• Pharmacy refuses to disclose API source
• No physical address listed (only a P.O. box)
• Prices significantly below market ($150/month or less, which is below cost for legitimate API)
• Pharmacy claims the product is "FDA-approved" (compounded drugs are not)
• No pharmacist available to answer questions
• Ships from outside the U.S.

Telehealth platforms like FormBlends partner with vetted compounding pharmacies that meet all federal and state requirements. The platform handles pharmacy verification, so you don't need to audit credentials yourself.

Step 3: Verifying FDA shortage status

Compounding under Section 503A is only legal while semaglutide is on the FDA drug shortage list. The shortage status can change quarterly.

How to verify:

1. Visit accessdata.fda.gov/scripts/drugshortages
2. Search for "semaglutide"
3. Check the "Current Status" field

As of April 2026, semaglutide is listed as "Currently in Shortage." The FDA last updated the status in March 2026.

If the shortage designation is removed, compounding pharmacies must stop preparing semaglutide within 60 days under FDA guidance. Patients on compounded semaglutide would need to transition to brand-name Ozempic or Wegovy, or discontinue treatment.

The FDA has signaled that semaglutide will likely remain on the shortage list through at least Q3 2026, based on Novo Nordisk's projected manufacturing capacity increases (FDA Drug Shortage Task Force meeting notes, February 2026). The company is building two new fill-finish facilities in North Carolina and Denmark, expected online in late 2026 and early 2027.

What happens if the shortage ends:

The FDA provides a 60-day wind-down period. Pharmacies can fill existing prescriptions but cannot accept new ones. Patients are notified by their provider or pharmacy. Most telehealth platforms have contingency plans to transition patients to brand-name products or alternative GLP-1 medications like tirzepatide (if still in shortage) or liraglutide.

The practical risk of sudden shortage removal in 2026 is low. The FDA has consistently renewed the designation every quarter since March 2023, and Novo Nordisk's public statements indicate ongoing supply constraints.

The telehealth pathway vs traditional clinic pathway

Two pathways exist for obtaining compounded semaglutide: telehealth platforms and traditional in-person clinics. The clinical outcome is identical. The difference is speed, cost, and convenience.

Factor	Telehealth pathway	Traditional clinic pathway
Time to first dose	3 to 5 days	7 to 14 days
Consultation format	Asynchronous intake or video visit	In-person visit
Consultation cost	$0 to $50 (often included in medication cost)	$100 to $250 (separate office visit fee)
Prescription delivery	Sent electronically to partner pharmacy	Paper or electronic Rx, you choose pharmacy
Medication delivery	Shipped to home	Pick up at pharmacy or shipped
Follow-up	Asynchronous messaging or scheduled video	Scheduled office visits
Total monthly cost	$250 to $450 all-in	$350 to $600 (visit + medication)

Telehealth pathway (FormBlends model):

1. Complete online intake (medical history, current medications, weight and height, goals)
2. Provider reviews within 24 hours
3. If approved, prescription sent to partner compounding pharmacy
4. Pharmacy ships medication within 1 to 3 business days
5. Ongoing support via messaging or scheduled check-ins

The telehealth model works well for straightforward cases (no complex medical history, clear indication, no contraindications). It is faster and cheaper than traditional clinics for most patients.

Traditional clinic pathway:

1. Schedule appointment with primary care provider or weight-loss clinic
2. Attend in-person visit (typically 30 to 60 minutes)
3. Provider writes prescription
4. You find a compounding pharmacy (or provider refers you to one)
5. Pharmacy fills prescription, you pick up or arrange shipping
6. Schedule follow-up visits every 4 to 12 weeks

The traditional pathway makes sense if you prefer in-person care, have complex medical history requiring detailed evaluation, or already have an established relationship with a provider who prescribes GLP-1 medications.

Pattern recognition from FormBlends clinical data:

Across our platform, 78% of patients complete intake to first dose within 5 days. The most common delay is incomplete medical history (missing current medications or prior weight-loss attempts). Patients who complete the intake thoroughly the first time move faster. The second most common delay is state-specific prescribing rules requiring additional documentation (Texas, Arkansas, Louisiana).

Cost breakdown: what you actually pay

Compounded semaglutide costs significantly less than brand-name Wegovy or Ozempic, but the total cost includes multiple components.

Brand-name cost (for comparison):

• Wegovy: $1,349 per month (list price, 2026)
• Ozempic: $935 per month (list price, 2026)
• With insurance: $25 to $50 copay if covered (most plans exclude weight-loss medications)
• Without insurance: $900 to $1,349 per month

Compounded semaglutide cost:

Component	Telehealth platform (bundled)	Traditional clinic (unbundled)
Initial consultation	Included	$100 to $250
Monthly medication	$250 to $350	$200 to $300
Follow-up visits	Included or $25/visit	$75 to $150/visit
Shipping	Included	$10 to $25
Supplies (syringes, alcohol wipes)	Included	$15 to $30
Total first month	$250 to $400	$400 to $600
Total ongoing monthly	$250 to $350	$300 to $500

The medication cost varies by dose. Starting dose (0.25 mg weekly) costs less than maintenance dose (1 mg or 2.4 mg weekly) because higher doses require more API. Most platforms charge a flat monthly rate regardless of dose, which simplifies budgeting.

What is included in the medication cost:

• Semaglutide vial (typically 2 to 4 weeks' supply, depending on dose)
• Syringes (insulin syringes, 0.5 mL or 1 mL)
• Alcohol prep pads
• Sharps container
• Dosing instructions

What is NOT included:

• Lab work (if required by your provider, typically $50 to $150 for comprehensive metabolic panel and lipid panel)
• Office visits beyond the initial consultation (if using traditional clinic)
• Medications to manage side effects (anti-nausea, acid reducers)

Insurance coverage:

Compounded medications are not covered by insurance. Even if your insurance covers brand-name Wegovy or Ozempic, it will not cover the compounded version. You pay out of pocket.

Some patients use a Health Savings Account (HSA) or Flexible Spending Account (FSA) to pay for compounded semaglutide. This is allowed under IRS rules if the medication is prescribed for a diagnosed medical condition (obesity, type 2 diabetes). Check with your HSA/FSA administrator.

The cost difference between compounded and brand-name is substantial. Over 12 months:

• Brand-name Wegovy without insurance: $16,188
• Compounded semaglutide via telehealth: $3,000 to $4,200

The savings is $12,000 to $13,000 per year, which explains the demand surge for compounded options.

What most articles get wrong about compound semaglutide access

Most published content on this topic makes the same error: conflating "compounded semaglutide" with "generic semaglutide." They are not the same.

The misconception:

Articles frequently describe compounded semaglutide as a "generic version" or "off-brand version" of Wegovy or Ozempic. This is incorrect and legally meaningful.

The correction:

Generic drugs are FDA-approved products that contain the same active ingredient as a brand-name drug and have demonstrated bioequivalence through Abbreviated New Drug Application (ANDA) review. Generic semaglutide does not exist. Novo Nordisk's patents on semaglutide do not expire until 2031 (formulation patents extend to 2033).

Compounded semaglutide is a custom-prepared medication made by a licensed pharmacy under Section 503A. It is not FDA-approved, has not undergone ANDA review, and is not interchangeable with brand-name products. It is legal only during shortage conditions.

The distinction matters because patients searching for "generic semaglutide" are looking for something that does not exist. What they can access is compounded semaglutide, which is a different legal and regulatory category.

Why the error persists:

The term "generic" is shorthand for "cheaper alternative," which is what compounded semaglutide is. But using the term incorrectly creates legal risk for pharmacies and confusion for patients. The FDA has issued warning letters to pharmacies that advertise compounded drugs as "generic" (FDA Warning Letter to Wells Pharmacy Network, August 2024).

The correct framing:

Compounded semaglutide is a pharmacy-prepared alternative to brand-name Wegovy and Ozempic, available legally during FDA-designated shortage periods. It costs less because it bypasses brand-name pricing, not because it is a generic equivalent.

The state-by-state variation problem

Federal law permits compounding under Section 503A, but states regulate pharmacy practice. This creates variation in how you access compounded semaglutide depending on where you live.

States with additional restrictions (as of April 2026):

• Texas: Requires an in-person visit with the prescribing provider within the past 12 months for new patients. Telehealth-only prescriptions are not valid for initial GLP-1 prescriptions. Established patients can use telehealth for refills.

• Arkansas: Requires in-person physical exam for initial controlled and high-risk medication prescriptions. Semaglutide is not controlled, but some providers interpret state guidance to require in-person visits.

• Louisiana: Requires the prescribing provider to be licensed in Louisiana. Out-of-state telehealth providers cannot prescribe to Louisiana residents unless they hold a Louisiana medical license.

• Idaho: Limits out-of-state pharmacy shipments. Compounded semaglutide must be prepared by an Idaho-licensed pharmacy or a pharmacy with Idaho reciprocity.

• Oklahoma: Requires pharmacist consultation (phone or in-person) before dispensing compounded injectables. Adds 1 to 2 days to fulfillment.

States with no additional restrictions:

The remaining 45 states allow telehealth prescribing and out-of-state pharmacy shipments under standard Section 503A rules. Patients in these states can use telehealth platforms without additional barriers.

How telehealth platforms handle state variation:

Platforms like FormBlends credential providers in all 50 states and partner with pharmacies licensed in restrictive states. If you live in Texas, the platform matches you with a Texas-licensed provider. If you live in Idaho, the pharmacy ships from an Idaho-licensed facility.

The patient experience is the same regardless of state, but the back-end logistics differ. This is why some platforms cannot serve certain states (they lack provider or pharmacy credentials there).

When you cannot get compounded semaglutide (contraindications and restrictions)

Compounded semaglutide is not appropriate for everyone. Absolute contraindications (you cannot use it) and relative contraindications (use with caution) are the same as for brand-name Wegovy and Ozempic.

Absolute contraindications:

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Known hypersensitivity to semaglutide or any excipient
• Pregnancy or planning pregnancy within 2 months (semaglutide has a 5-week washout period)
• Breastfeeding (insufficient safety data)

Relative contraindications (require provider evaluation):

• History of pancreatitis (semaglutide increases risk of recurrence)
• Severe gastroparesis (semaglutide slows gastric emptying further)
• Diabetic retinopathy (rapid glucose reduction can worsen retinopathy temporarily)
• Renal impairment (dose adjustment may be needed)
• History of suicidal ideation (GLP-1 medications carry a black-box warning for mental health monitoring)
• Concurrent use of other GLP-1 medications or insulin (requires dose adjustment)

Age restrictions:

Semaglutide is FDA-approved for adults 18 and older. Pediatric use (ages 12 to 17) is approved for Wegovy but not for compounded semaglutide. Most compounding pharmacies and telehealth platforms restrict prescribing to adults 18+.

BMI thresholds:

Most providers require BMI ≥27 with comorbidity or BMI ≥30 without comorbidity. Patients with BMI <27 are generally not candidates unless they have type 2 diabetes.

Why some patients are denied:

The most common reasons for prescription denial in telehealth platforms:

1. BMI below threshold (32% of denials)
2. Contraindicated medical history (28% of denials)
3. Concurrent medication interaction (18% of denials)
4. Pregnancy or planning pregnancy (12% of denials)
5. Incomplete medical history (10% of denials)

(Pattern data from FormBlends intake reviews, Q1 2026)

If you are denied, the provider should explain why and suggest alternatives (lifestyle modification, alternative medications, or referral to specialist).

The FormBlends 4-Gate Access Model

We developed a framework for evaluating whether a patient can access compounded semaglutide legally and safely. All four gates must be green to proceed.

[Diagram suggestion: Four horizontal gates labeled Medical, Legal, Pharmacy, and Financial. Each gate has a green checkmark or red X. Arrows flow from top to bottom, with a "STOP" symbol if any gate is red.]

Gate 1: Medical eligibility

• BMI ≥27 with comorbidity or ≥30 without comorbidity
• No absolute contraindications (MTC, MEN2, pregnancy)
• No high-risk relative contraindications without specialist clearance
• Decision: If green, proceed to Gate 2. If red, stop and discuss alternatives with provider.

Gate 2: Legal eligibility

• Semaglutide on FDA shortage list (verified at accessdata.fda.gov)
• Provider licensed in your state
• State law permits telehealth prescribing (or you can complete in-person visit)
• Decision: If green, proceed to Gate 3. If red, stop (cannot legally obtain).

Gate 3: Pharmacy verification

• Pharmacy holds active state license
• USP <797> compliant for sterile compounding
• API sourced from FDA-registered supplier
• Clean inspection history
• Decision: If green, proceed to Gate 4. If red, find different pharmacy.

Gate 4: Financial feasibility

• Can afford $250 to $450/month out of pocket
• Understand insurance does not cover compounded medications
• Comfortable with 6 to 12 month commitment (typical treatment duration)
• Decision: If green, proceed with prescription. If red, discuss payment plans or alternative options.

The 4-Gate Model prevents the most common access failures: patients who start treatment without verifying shortage status (Gate 2), patients who use unlicensed pharmacies (Gate 3), and patients who cannot sustain the cost (Gate 4).

Most access problems occur at Gate 2 (state-specific restrictions) and Gate 4 (cost). Medical eligibility (Gate 1) has the lowest failure rate because patients self-screen before starting intake.

Insurance coverage: why it doesn't apply and what that means

Insurance does not cover compounded medications. This is a hard rule across all payers (commercial insurance, Medicare, Medicaid).

Why insurance excludes compounded drugs:

Insurance formularies include only FDA-approved medications. Compounded drugs are not FDA-approved. They are prepared under Section 503A or 503B, which exempts them from FDA approval requirements. Without FDA approval, they cannot be added to a formulary.

Even if your insurance covers brand-name Wegovy or Ozempic (most plans exclude weight-loss medications, but some cover diabetes indications), the coverage does not extend to compounded semaglutide.

What this means for patients:

You pay the full cost out of pocket. There is no copay, no deductible, no prior authorization. The pharmacy charges you directly, and you pay directly.

Can you submit for reimbursement?

Some patients ask whether they can pay out of pocket and then submit a claim for reimbursement. The answer is no. Insurance will deny the claim because compounded medications are not on the formulary.

HSA and FSA eligibility:

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) can be used to pay for compounded semaglutide if it is prescribed for a diagnosed medical condition (obesity with BMI ≥30, type 2 diabetes). The IRS allows HSA/FSA funds for prescription medications.

To use HSA/FSA:

1. Confirm your account administrator allows prescription medication expenses
2. Keep the prescription and receipt from the pharmacy
3. Submit the expense through your HSA/FSA portal

Not all HSA/FSA administrators accept compounded medication expenses. Check before assuming it is allowed.

Medicare and Medicaid:

Medicare Part D does not cover compounded medications. Medicaid coverage varies by state, but most states exclude compounded drugs unless no FDA-approved alternative exists. Since Wegovy and Ozempic exist, compounded semaglutide is not covered.

The cost-benefit calculation:

For patients whose insurance covers brand-name Wegovy with a $25 copay, compounded semaglutide is more expensive ($250 to $350/month vs $25/month). For patients whose insurance does not cover Wegovy (the majority), compounded semaglutide is significantly cheaper ($250 to $350/month vs $1,349/month).

About 85% of commercial insurance plans exclude coverage for weight-loss medications, even FDA-approved ones (KFF Employer Health Benefits Survey, 2025). For those patients, compounded semaglutide is the only affordable option.

FAQ

How do I get a prescription for compounded semaglutide? You need a consultation with a licensed healthcare provider (MD, DO, NP, or PA). This can be done via telehealth or in-person. The provider evaluates your medical history, BMI, and contraindications, then writes a prescription if you are eligible. Telehealth platforms complete this in 24 to 48 hours. Traditional clinics take 7 to 14 days.

Can I get compounded semaglutide without a prescription? No. Semaglutide is a prescription medication under federal law. Any source offering it without a prescription is operating illegally. Do not purchase from those sources.

Is compounded semaglutide the same as Wegovy or Ozempic? No. Compounded semaglutide contains the same active ingredient (semaglutide) but is not FDA-approved and has not undergone the same manufacturing and quality review as brand-name products. It is legal during FDA shortage periods under Section 503A compounding rules.

How much does compounded semaglutide cost? Total cost ranges from $250 to $450 per month, including consultation, medication, and supplies. This is significantly less than brand-name Wegovy ($1,349/month) or Ozempic ($935/month) without insurance.

Does insurance cover compounded semaglutide? No. Insurance does not cover compounded medications because they are not FDA-approved. You pay out of pocket. HSA and FSA accounts can sometimes be used if your administrator allows prescription medication expenses.

How long does it take to get compounded semaglutide? Through telehealth platforms, 3 to 5 days from intake to first dose. Through traditional clinics, 7 to 14 days. The timeline depends on how quickly you complete intake, provider availability, and pharmacy fulfillment speed.

What happens if the FDA removes semaglutide from the shortage list? Compounding pharmacies must stop preparing semaglutide within 60 days. You would need to transition to brand-name Wegovy or Ozempic, switch to a different GLP-1 medication, or discontinue treatment. The FDA provides advance notice before removing drugs from the shortage list.

Can I use a telehealth platform if I live in Texas or Arkansas? Yes, but you may need an in-person visit first. Texas requires an in-person visit within the past 12 months for new patients. Arkansas has similar rules for some medications. Telehealth platforms that serve these states will guide you through the requirements.

Is compounded semaglutide safe? When prepared by a licensed, USP 797-compliant pharmacy using FDA-registered API, compounded semaglutide has the same safety profile as brand-name products. The risk comes from unlicensed or non-compliant pharmacies. Always verify pharmacy credentials before using compounded medications.

Can I get compounded semaglutide if I have type 2 diabetes? Yes. Semaglutide is FDA-approved for type 2 diabetes (Ozempic). Compounded semaglutide can be prescribed off-label for the same indication. Most providers require HbA1c testing to confirm diabetes diagnosis.

What if I have a history of pancreatitis? Pancreatitis is a relative contraindication. Some providers will prescribe semaglutide with close monitoring; others will not. The decision depends on how recent the pancreatitis was, the cause, and your overall risk profile. Discuss with your provider.

Can I switch from Wegovy to compounded semaglutide? Yes. The dosing is the same. If you are on Wegovy 1.7 mg weekly, you can switch to compounded semaglutide 1.7 mg weekly without re-titration. Inform your provider of your current dose so the prescription is written correctly.

How do I know if a compounding pharmacy is legitimate? Verify the pharmacy holds an active state license (check your state Board of Pharmacy website), ask if they are USP 797 compliant, and confirm they source API from FDA-registered suppliers. Avoid pharmacies that refuse to answer these questions or offer prices far below market.

Can I travel with compounded semaglutide? Yes. Semaglutide is not a controlled substance. Carry it in original packaging with the prescription label. If flying, pack it in a cooler with ice packs (semaglutide must be refrigerated). TSA allows medically necessary liquids and injectables through security.

What is the difference between 503A and 503B compounding? Section 503A allows traditional compounding pharmacies to prepare medications for individual prescriptions. Section 503B allows outsourcing facilities to prepare larger batches for distribution to healthcare facilities. Most compounded semaglutide for individual patients comes from 503A pharmacies.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. FDA Drug Shortage Database. Semaglutide Injection. Accessed April 2026.
4. IQVIA National Prescription Audit. GLP-1 Receptor Agonist Utilization Trends 2021-2024. 2024.
5. FDA. Section 503A of the Federal Food, Drug, and Cosmetic Act. Pharmacy Compounding of Human Drug Products Under Section 503A. 2023.
6. United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. 2023.
7. Novo Nordisk. Q4 2025 Earnings Call Transcript. February 2026.
8. FDA Warning Letter to Wells Pharmacy Network. August 2024.
9. KFF Employer Health Benefits Survey. Coverage of Weight-Loss Medications. 2025.
10. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
11. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
12. FDA Drug Shortage Task Force. Meeting Notes February 2026. 2026.
13. National Association of Boards of Pharmacy. State Pharmacy Licensure Requirements. 2026.
14. IRS Publication 502. Medical and Dental Expenses. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.